Poly Medicure (POLYMED) Fundamentals 2026 — P/E 52.7x, Revenue Analysis | SniperIQ
Poly Medicure (POLYMED) is a India-listed Healthcare company in Medical - Instruments & Supplies with a market capitalization of ₹16,928 Crore, trading at ₹1670.20 on the BSE. This SniperIQ fundamentals page covers Poly Medicure's valuation (P/E 52.7x, P/B 5.5x), profitability (net margin 17.2%), revenue (₹1,875 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Poly Medicure's market cap?
Poly Medicure (POLYMED) has a market capitalization of approximately ₹16,928 Crore, trading at ₹1670.20 on the BSE. Market cap moves with the live share price.
What is Poly Medicure's P/E ratio?
Poly Medicure's trailing twelve-month P/E ratio is 52.7x, with a price-to-book (P/B) of 5.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Poly Medicure?
Poly Medicure runs a net profit margin of 17.2%, a gross margin of 46.5%, and an operating margin of 17.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Poly Medicure generate?
Poly Medicure reported revenue of ₹1,875 Crore for fiscal year 2026, with net income of ₹322 Crore and earnings per share (EPS) of 31.79. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Poly Medicure pay a dividend?
Poly Medicure offers a trailing dividend yield of about 0.2%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Poly Medicure financially healthy?
Poly Medicure carries a debt-to-equity ratio of 0.11x and a current ratio of 3.37x, with a market beta of 0.02. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Poly Medicure a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Poly Medicure (POLYMED) the key facts are: market cap ₹16,928 Crore, P/E 52.7x, revenue ₹1,875 Crore, 52-week range 1184-2143.6. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Poly Medicure's full fundamentals live
Get Poly Medicure's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.